CapForce Inc. (CFOR)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 4 | 4 | 3 | 3 | 5 | 30 | 76 | - |
| Operating profit | $m | 24 | 65 | ||||||
| Net profit | $m | -26 | -35 | -37 | -33 | 12 | 24 | 62 | - |
| EPS reported | $ | 2.32 | 5.34 | ||||||
| Operating cashflow per share | $ | -0.12 | -0.12 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.12 | -0.12 | ||||||
| Free cash flow | $m | -1 | -2 | ||||||
| Net debt | $m | -0 | 0 | ||||||
| Book value equity | $m | 32 | 74 | ||||||
| Book value per share | $ | 3.15 | 5.95 | ||||||
| Number of shares | m | 10.13 | 12.49 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 6.85 | 2.17 | ||||||
| P/B LTM | x | 5.03 | 2.16 | ||||||
| P/S LTM | x | 5.30 | 2.10 | ||||||
| P/FCF LTM | x | -135.35 | -105.37 | ||||||
| EV/EBITDA LTM | x | 6.67 | 2.48 | ||||||
| EV/Sales LTM | x | 5.35 | 0.73 | ||||||
| Earnings Yield LTM | % | +14.60% | +46.08% | ||||||
| FCF Yield | % | -0.74% | -0.95% | ||||||
| Quality | |||||||||
| ROE | % | +74.14% | +168.84% | ||||||
| ROIC | % | +71.11% | +83.36% | ||||||
| Operating margin | % | +79.56% | +84.82% | ||||||
| Gross margin | % | +90.00% | +89.53% | ||||||
| FCF/Sales | % | -3.92% | -2.00% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +0.87% | +132.17% | ||||||
| Sales Growth YoY | % | +481.20% | +1366.47% | ||||||
| Net Income Growth YoY | % | +96.95% | +419.30% | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | +5909.20% | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.61 | -0.78 | ||||||
| Net Debt/EBITDA | x | 0.06 | 0.03 | ||||||
| EBIT/Net interest | x | -2,136.78 | 6,880.62 | ||||||
| Net debt/market cap | % | +0.05% | +0.79% | ||||||
| Net debt/Equity | x | -0.01 | 0.00 | ||||||
| Gross debt/equity | x | 0.06 | 0.03 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
CapForce Inc. is a precision medicine company dedicated to developing and commercializing sophisticated molecular microbiology solutions. Its mission is to address life-threatening infectious diseases for patients in the United States and across international markets. The company's diverse product range includes Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel diagnostic tests, and SARS CoV-2 testing kits. Beyond its product line, CapForce extends its offerings to include laboratory services, collaboration services (such as funded software arrangements), and licensing agreements. Additionally, the company provides listing sponsorship and consultancy services. Formerly known as OpGen, Inc., the entity officially changed its name to CapForce Inc. in February 2026. CapForce Inc. was established in 2001 and maintains its headquarters in Clarksburg, Maryland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
CapForce Inc. is a precision medicine company dedicated to developing and commercializing sophisticated molecular microbiology solutions. Its mission is to address life-threatening infectious diseases for patients in the United States and across international markets. The company's diverse product range includes Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel diagnostic tests, and SARS CoV-2 testing kits. Beyond its product line, CapForce extends its offerings to include laboratory services, collaboration services (such as funded software arrangements), and licensing agreements. Additionally, the company provides listing sponsorship and consultancy services. Formerly known as OpGen, Inc., the entity officially changed its name to CapForce Inc. in February 2026. CapForce Inc. was established in 2001 and maintains its headquarters in Clarksburg, Maryland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free